Search or add a thesis

Advanced Search (Beta)
Home > Association of Anril Gene With Cancer

Association of Anril Gene With Cancer

Thesis Info

Author

Burhanullah

Supervisor

Zehra Agha

Department

Department of Biosciences

Program

BBS

Institute

COMSATS University Islamabad

Institute Type

Public

City

Islamabad

Province

Islamabad

Country

Pakistan

Thesis Completing Year

2017

Thesis Completion Status

Completed

Subject

Biosciences

Language

English

Added

2021-02-17 19:49:13

Modified

2023-01-06 19:20:37

ARI ID

1676719648618

Similar


Loading...
Loading...

Similar Books

Loading...

Similar Chapters

Loading...

Similar News

Loading...

Similar Articles

Loading...

Similar Article Headings

Loading...

86. Al-Tariq/The Star of Brilliant Brightness

86. Al-Tariq/The Star of Brilliant Brightness

I/We begin by the Blessed Name of Allah

The Immensely Merciful to all, The Infinitely Compassionate to everyone.

86:01
a. By the celestial realm and the Tariq.

86:02
a. And what may enable you to comprehend the Tariq?

86:03
a. Tariq is the star of brilliant brightness before dawn.

86:04
a. There is a guardian angel set up over every human being.

86:05
a. So let every human being reflect of what insignificant substance he is created -

86:06
a. - he is created out of a mingling of seminal and ovarian spurting fluid,

86:07
a. emerging from between the male’s hip and the female’s pelvis.

86:08
a. Surely, HE is Able to bring him back to life-

86:09
a. - at the Time when all secrets of his deeds, dealings and speech will be exposed and judged,

86:10
a. then he will have no power to hide them, and
b. no supporter to help him avoid the consequences.

86:11
a. By the sky clouds giving rain, time and again,

86:12
a. and the land/earth too splitting time and again -
b. for gushing of springs and growth of vegetation.
c. and human beings during the Time of Resurrection.

728 Surah 86 * Al-Tariq

86:13
a. Indeed, this - Qur’an - is the Decisive Word!

86:14
a. And it is not for amusement.

86:15
a. Indeed, they are devising a plot/false arguments against The Prophet,

86:16

Concept of Islamic Leadership in Syed Muhammad Naquib Al-Attas’s Philosophy

Islamic leadership is defined as a divine trust (amanah) from Allah, based on the Tauhidic paradigm of oneness of Allah that is focusing to serve HIM as HIS servant, while at the same time be the servant of Allah, perform the role of Khalefah (vicegerent) of Allah fully adheres to the Sunnah central to Islamic personality, characteristics and aklaq (Islamic moral and ethical) that was exemplified by the prophet (s.a.w), leading followers to the organization goals and to the straight path of the success in the Hereafter. It is based on this adopted definition that the paper tries to look into the notion from perspective of a Malaysian Muslim Philosopher to the core, Syed Muhammad Naquib Al-Attas, who believes in delivering amanah given to him, and at the same time perform the role of vicegerent of Allah. He suggests that lack of good leaders or rise of unqualified and false ones is one of the major problems of Ummah. Content analysis approach is engaged on both primary and secondary data collected. That is to say, it is a qualitative research in nature. The finding shows that the basis of Al-Attas’s concept of leadership is entrenched in Al-Qur’an and the tradition of the prophet in addition to his deep understanding on the Islamic Sciences such as Islamic theology, philosophy, and metaphysis and so on.

Factors Associated With Cardiac Dysfunction Following Anthracyline-Based Chemotherapy in Adults in a Tertiary Hospital in Nairobi

Introduction: Anthracyclines are known to improve survival in some malignancies, but may also be associated with irreversible cardiotoxicity, which is partly dose dependent. Early detection of cardiotoxicity provides an opportunity for treatment adjustment. Several parameters predict development of clinically manifest cardiac dysfunction. The study aimed to evaluate clinical and echocardiographic parameters which predict development of cardiac dysfunction in a sub-Saharan African population. Methods: Patients with a diagnosis of cancer and receiving anthracyclines at AKUH,N were evaluated if they met eligibility criteria (≥18years at first anthracycline administration, archived baseline echocardiogram, no prior history of heart disease or use of anthracyclines). Patients underwent echocardiographic, baseline clinical , drug therapy, radio-therapy and cardiovascular risk factor assessments. Echocardiographic global longitudinal strain (GLS), left ventricular (LV) ejection fraction and LV volumes were assessed. A relative decline from baseline in GLS of >15%, an absolute decline in LVEF >10 percentage points to <53%, or symptomatic absolute decline in LVEF of 6-10 percentage points to <53% defined LV dysfunction (cases). Factors associated with development ofLV dysfunction were compared between cases and controls (no LV dysfunction). Results: From 14-Oct-2013 to 11-Apr-2019, 504 patients who received anthracyclines were screened. 141 fullfilled inclusion criteria and were analysed (mean age, 47.7 years ± 11.2, Africans 95%, females 85.1%). Breast cancer patients were 82%, lymphoma 12%, sarcoma 5%, and leukaemia 1%. 39 (27.7%) had cardiac dysfunction, 30 of whom fulfilled the GLS criterion. Mean time interval between echocardiograms was 14.3 months (cases 16.4 ± 16.9; controls 14.4 ± 13.2), mean anthracycline dose was 244.7mg/m2 ± 72.2 (cases 254.5 ± 78.7; controls 241 ± 69.6), and mean symptom scores (DASI) were 50.0 ± 13.3 (cases 48.5 ± 13.4; controls 50.5 ± 13.2). Mean cardiotoxic doxorubicin equivalence dose was 236.7 mg/m2 ± 57.4 for cases and 217.3 ± 61.9 for controls [p = 0.033, OR = 1.00 (95% CI: 0.99 - 1.01)]. Cycle intervals, body surface area, body mass index, blood pressure, age, concomitant medication, radiation use and cardiovascular factors were similar. Echocardiographic parameters – E/a ratio and e’ were significantly reduced in cases (E/a 1.02 ± 0.33 for cases vs 1.16 ± 0.36 for controls, p =0.02: e’ 0.10 ± 0.05 for cases vs 0.11 ± 0.05 for controls, p =0.011). Conclusion: This is the first study evaluating early cardiotoxicity in an adult Sub-Saharan population receiving standard dose anthracyclines. The incidence of early cardiotoxicity was 27.7%, which was higher than in previously studied